Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Position Raised by Alliancebernstein L.P.

Alliancebernstein L.P. boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 326,802 shares of the medical equipment provider’s stock after acquiring an additional 22,784 shares during the period. Alliancebernstein L.P.’s holdings in Zimmer Biomet were worth $34,520,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ZBH. Hazlett Burt & Watson Inc. lifted its holdings in shares of Zimmer Biomet by 23.7% in the 4th quarter. Hazlett Burt & Watson Inc. now owns 815 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 156 shares during the last quarter. Bcwm LLC bought a new position in shares of Zimmer Biomet during the fourth quarter worth about $1,982,000. United Bank lifted its position in Zimmer Biomet by 6.7% in the 4th quarter. United Bank now owns 9,426 shares of the medical equipment provider’s stock valued at $996,000 after purchasing an additional 589 shares during the last quarter. Allianz SE bought a new position in Zimmer Biomet in the 4th quarter worth about $3,099,000. Finally, Intrust Bank NA increased its stake in shares of Zimmer Biomet by 31.4% in the fourth quarter. Intrust Bank NA now owns 2,872 shares of the medical equipment provider’s stock valued at $303,000 after purchasing an additional 687 shares during the period. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Trading Down 4.6 %

NYSE:ZBH opened at $107.46 on Friday. The stock has a market cap of $21.39 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $97.69 and a fifty-two week high of $129.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock’s 50-day moving average is $107.32 and its two-hundred day moving average is $107.22.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the firm earned $2.20 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. Zimmer Biomet’s payout ratio is 21.57%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ZBH. JMP Securities reissued a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a report on Friday, February 7th. Truist Financial reaffirmed a “hold” rating and issued a $113.00 price objective (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays decreased their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Finally, Raymond James decreased their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $124.15.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the sale, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.70% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.